Key takeaways
Rybelsus (semaglutide) and metformin (Glumetza) are both oral medications used to treat Type 2 diabetes, but they belong to different medication classes. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist, while metformin is a biguanide. Rybelsus is taken once daily on an empty stomach, whereas metformin is typically taken once or twice daily with food to minimize stomach upset. Rybelsus is only available as a brand-name medication, while metformin is available in both generic and brand-name forms. Common side effects of Rybelsus include nausea, vomiting, and diarrhea, and it carries a risk of thyroid cancer. Metformin can cause diarrhea, nausea, and gas, and it has a rare but serious risk of lactic acidosis (excess acid in the blood). Rybelsus can interact with other medications by affecting their absorption, while metformin's interactions are more related to its potential to cause low blood sugar when combined with other diabetes medications.
